Latest Development Activity News

Terra Metals has raised $15 million through an institutional placement led by cornerstone investors to fast-track exploration and development at its polymetallic Dante Project in Western Australia.

Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.

GemLife Communities Group has reported a robust first half of FY25, exceeding its prospectus forecasts across revenue, earnings, and home settlements, while reaffirming full-year guidance backed by a recent $750 million IPO.

GemLife Communities Group has reported a strong first half of FY25, exceeding Prospectus forecasts with higher home settlements and premium sales, while confirming full-year guidance. The company’s extensive development pipeline and commitment to sustainability initiatives position it well for continued growth in the Australian Land Lease Community sector.

Weebit Nano Limited reported a strong FY25 with revenues surging over fourfold to $4.4 million and a narrowed net loss of $38.4 million, driven by key licensing deals and progress towards automotive-grade ReRAM qualification.

Ark Mines Ltd is fast-tracking its Sandy Mitchell rare earths project in Queensland, backed by a $4.5 million investment from the Queensland Investment Corporation and targeting production by late 2027.

Horizon Oil and its partners have secured a ten-year extension for the Maari oilfield permit in New Zealand, enabling continued production and strategic planning through 2037. This comes as the field hits its highest output in over five years.

Neuren Pharmaceuticals reported a robust half-year with an 88% increase in net profit, driven by rising royalties from DAYBUE™ sales and progress in its NNZ-2591 clinical program. The company also completed a $39.6 million share buy-back, underscoring confidence in its growth trajectory.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Arafura Rare Earths has successfully completed the first tranche of its A$80 million capital raising, issuing 369.6 million new shares and securing A$70.2 million before costs. The remaining tranche awaits shareholder approval.